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Abstract  
Major depressive disorder is a psychiatric illness that is associated with a variety of debilitating 
symptoms such as persistent sadness, lack of interest and motivation, lassitude, pessimistic 
thoughts, and in severe cases, suicidal ideation and behavior. Current psychological and 
pharmacological treatments have been demonstrated efficacious; however, an ever-growing 
number of individuals frequently report minimal to no improvement with these treatments; and 
in some cases, a worsening of symptoms. This inadequacy to treatment is commonly known as 
treatment-resistant depression. At Kadima Neuropsychiatry Institute, Dr. Feifel treats individuals 
with treatment-resistant depression with advanced treatments such as TMS and ketamine. During 
my fieldwork internship at Kadima Neuropsychiatry Institute, my project focused on evaluating 
the efficacy of ketamine administered intramuscular to patients with treatment-resistant 
depression and determining which characteristics of a patient’s psychedelic experience or “trip” 
is associated with the decrease in their depressive symptoms. The results of this project 
demonstrated that an initial low dose of ketamine was significantly quick and efficacious in 
decreasing depressive symptoms in patients with treatment resistant depressive. In addition, a 
first of its kind exploratory analysis suggested that the intensity, positive content, and 
dissociative characteristics of a ketamine induced psychedelic trip were strongly associated with 
the decrease in depressive symptoms. Despite the significance in these results, more research 
needs to include a larger sample and explore the specific subjective characteristics within a 
psychedelic “trip” to further understand its association with a decrease in depressive symptoms. 
The quick and efficacious antidepressant effects of ketamine demonstrated in this project provide 
much potential for a program involving a mobile ketamine clinic to address severe depression 
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and suicidality. Such therapeutic and intervention potentials can be explored further given an 
expansion of current policy limiting ketamine as a schedule III substance.   
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Introduction 
Major depressive disorder is a burdensome psychiatric disorder that affects an 
individual's emotional, physical, and social abilities. Symptoms of major depressive disorder 
often include feelings of emptiness, diminished interest or pleasure in activities, decrease or 
increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, 
feelings of worthlessness, concentration difficulties, and, in severe cases, suicidal ideation and 
behavior, (American Psychiatric Association, 2013).  According to the World Health 
Organization, depression is ranked as the leading cause of disability worldwide (Murry et. al., 
1996). In addition, depression has been shown to be associated with a 15.9% risk of lifetime 
suicide attempt (Chen & Dilsaver, 1996). Despite the available psychological, pharmacological, 
and non-pharmacological treatment options for depression, a vast majority of individuals who 
have tried one or more of these options often report minimal to no improvement of their 
depressive symptoms. Researchers have defined this as treatment-resistant depression (Fava, 
2003). Treatment-resistant depression is an ever-emerging category of major depressive disorder 
that physicians and researchers are determined to tackle.   
Epidemiology of Major Depressive Disorder  
A major depressive episode and a subsequent diagnosis of major depressive disorder can 
happen to anyone regardless of their age, gender, ethnicity, or socioeconomic status. The 
American Psychological Association (2013) defines a major depressive episode as a “persistent 
depressed mood and the inability to anticipate happiness or pleasure,” in a 2-week period that is 
represents a change from an individual's previous functioning. Between 2005 and 2014, 15.7 
million people experienced a major depressive episode within the past years, in which 4.3% of 
adults 18 years and older had severe functional impairment, (Hedden et al., 2014). Furthermore, 
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the percentage of having a major depressive episode within the past year is highest for young 
adults aged 18-25 (9.3%), trailed by adults ages 26 to 49 (7.2%), then by those 50 years and 
older (5.2%). Although more prevalent in adolescents and adults, the prevalence rate of 
depression for children between ages of 3 to 17 is 2.1%, (Perou et al., 2013). The typical age-of-
onset for major depressive disorder commonly begins in the early to mid-twenties. Individuals 
who experienced a major depressive episode during their adolescence and young adulthood are 
more likely to experience recurrent and severe major depressive episodes, causing severe 
psychosocial difficulties throughout adulthood, (Wilson et al., 2015). Women have been found to 
have a higher rate of a major depressive episode (9.5%) compared to men (5.6%) in all age 
groups, (Pratt & Brody 2014). Another main demographic that contributes to the rate of major 
depressive disorder is ethnicity. Severe depression rates have been found to be lower among 
Non-Hispanic white persons (2.6%) than Hispanic (3.7%) and Non-Hispanic black persons 
(4.1%); however, Non-Hispanic whites (37.0%) were found to seek a mental health care 
professional for severe depressive symptoms more than Hispanic (27.8%) and Non-Hispanic 
black (33.6%) persons (Pratt & Brody, 2014). Lastly, socioeconomic status contributes a major 
role in the onset of major depressive disorder. Individuals living below the poverty line are twice 
as likely to experience depressive symptoms than individuals living at or above the poverty level, 
(Pratt & Brody, 2014).  
Given the range of individuals that suffer from moderate to severe major depressive 
disorder, a number of standard psychological, pharmacological, and non-pharmacological 
treatment options are available to attempt to alleviate the depressions debilitating symptoms. 
Despite the available treatment options for major depressive disorder, these treatment options are 
often reported to be non-efficacious or harmful.  
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Major Depressive Disorder Treatment 
Cognitive behavioral therapy is a psychological treatment for depression that teaches 
patients strategic coping methods to address daily stressors and unhealthy thought patterns. This 
form of psychotherapy aims to modify and correct maladaptive psychological processes in order 
to boost an individual's happiness and positive cognition. Cuijpers et al. (2013) conducted a 
meta-analysis of cognitive behavioral therapy, and determined that the efficacy of psychotherapy 
is well supported; yet the long-term effects have been reported to be unfavorable, small, or even 
absent, (Conradi et al., 2017).  
 In general, individuals would rather seek pharmacological antidepressant medication 
rather than psychotherapy, yet antidepressant medication oftentimes demonstrate non-efficacy 
and intolerability. Jain et al. (2011) explained that achieving full remission takes adequate 
duration and dosage of antidepressants yet, individuals are reluctant to continue a prescribed 
regimen due to adverse side effects. Common complaints of antidepressant treatment, 
specifically SSRIs, are dry mouth, nausea, sleep disturbances, weight gain, sexual dysfunction, 
and suicidal ideation, (Ferguson, 2001; Zisook et al., 2009). In addition, 43% of individuals often 
report an inadequate response to the first line of antidepressant treatment; and 65-67% of 
individuals given a subsequent antidepressant trial had worse treatment compliance, due to 
perceived lack of treatment response and disease severity (Sicras-Mainar, et al., 2012). 
Other than psychological and pharmacological treatment options, individuals will then 
turn to non-pharmacological treatments such as transcranial magnetic stimulation. Transcranial 
magnetic stimulation uses magnetic stimulations to activate deep brain regions and their 
interconnecting fibers to affect the mechanisms involved in the pathophysiology of depression, 
including the rewarding, motivation, and pleasure circuits. A full treatment cycle of transcranial 
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magnetic stimulation consists of a strict treatment schedule of thirty-six, twenty-minute daily 
treatment session at an outpatient psychiatry clinic. Levkovitz et al. (2015) demonstrated the 
efficacy of repetitive transcranial magnetic stimulation in treating individuals with major 
depressive disorder; yet also found that transcranial magnetic stimulation causes adverse side 
effects such as headaches and insomnia. Health Quality Ontario (2016) reviewed twenty-three 
randomized controlled trials of transcranial magnetic stimulation for treatment of treatment-
resistant depression and concluded that there is a small, short-term effect compared to sham 
(placebo) treatment. Furthermore, results from the meta-analysis favored electroconvulsive 
therapy over transcranial magnetic stimulation for treating major depressive disorder.    
In most severe cases of depression, individuals will often seek electroconvulsive therapy 
(ECT) as a last resort to gain remission. ECT is a procedure done under general anesthesia, in 
which small electrical currents are delivered to the brain, causing short seizures and, in turn, 
reversing symptoms of depression. A review of the efficacy of ECT demonstrated that the 
remission rate of ECT is short and often plagued with considerable cognitive side effects, which 
has been found to be worse among older populations (Charlson et al., 2012; Kumar et al., 2013).   
Treatment-Resistant Depression and Ketamine 
Treatment resistance to standard treatment options for depression are evident and 
disabling, validating treatment-resistant depression as a public health concern. Treatment-
resistant depression is an emerging category of depression among individuals who have tried and 
failed prior treatments. Fava (2003) suggests that treatment-resistant depression is an inadequate 
response to at least one antidepressant trial of adequate doses and duration. Little (2003) defines 
treatment-resistant depression as being resistant (failure to produce significant clinical 
improvement) to at least two trials with antidepressants (adequate in dose, duration, and 
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compliance). Although definitions of treatment-resistant depression vary, the general and widely 
accepted criteria of treatment-resistant depression include: a clear diagnosis of major depressive 
disorder and treatment inadequacy and response to previous treatment trials, (Souery, et al., 
1999).  
In recent times, psychiatrist have been treating patients who have treatment-resistant 
depression with subanesthetic doses of ketamine, a common anesthetic that has been used since 
1970.  Subanesthetic doses of ketamine regularly produces dissociative, psychedelic, and most 
importantly, strong antidepressant effects. Subanesthetic doses of ketamine received 
intravenously have been demonstrated to produce quick and efficacious antidepressant effects 
when treatment individuals with treatment-resistant depression, (Feifel et al., 2017). Moreover, 
Xu et al., (2015) conducted a systematic review of 9 trials of ketamine treatment and concluded 
that low-doses of ketamine produce quick antidepressant effects; and showed a significant effect 
in reducing in suicidality within 1 to 3 days after treatment.  
At present, treatment-resistant depression is a well-recognized category of depression that 
seems to be ever-growing. In light of inefficacious and intolerable standard treatments, 
physicians and researchers are at the forefront of exploring new breakthrough treatment options. 
Dr. David Feifel, the owner of Kadima Neuropsychiatry Institute, is one of those researchers at 
the forefront leading the way forward for breakthrough treatments like ketamine.  
Scope of Work 
Kadima Neuropsychiatry Institute is a specialty outpatient psychiatry clinic led by Dr. 
David Feifel who is an expert clinician and certified neuropsychiatrist. The mission at Kadima 
Neuropsychiatry Institute is to provide advanced therapeutic treatments such as repetitive 
transcranial magnetic stimulation (rTMS) and ketamine to individuals suffering from psychiatric 
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disorders, specifically treatment-resistant depression and posttraumatic stress disorder (PTSD). 
In addition, patients have the option of participating in sponsored clinical trials that investigates 
new psychiatric treatments. Overall, the vision of Kadima Neuropsychiatry Institute is to treat 
patients who are treatment-resistant to standard treatments for depression, while providing 
clinical evidence of the effectiveness and safety of new, breakthrough treatments for psychiatric 
disorders. To achieve the aforementioned, Dr. Feifel employs a team of six qualified health 
professionals: a chief finance officer, two registered nurses, two clinical research coordinators, 
and a medical biller/research assistant.  
Given the robust clinical evidence of the quick antidepressant effects of ketamine 
(Drewniany et al., 2015; Feifel et al., 2017; Kishimoto et al., 2016), Dr. Feifel set up my 
fieldwork internship at Kadima Neuropsychiatry Institute to add to the literature of the efficacy 
of ketamine, and investigate what characteristics of a ketamine-induced psychedelic experience 
are important to a patient’s decrease in depressive symptoms. See Appendix A for goals and 
objectives. My project focused on evaluating the efficacy of an initial dose of 0.25 mg/kg of 
ketamine administered intramuscular (IM) to real world patients with treatment-resistant 
depression and determining which characteristic of a patient’s psychedelic experience or “trip” is 
associated with the decrease in their depressive symptoms. This project added to unanalyzed data 
that was collected at Dr. Feifel’s outpatient clinic at the University of California, San Diego 
(UCSD). The dataset included 15 patients who received 0.25 mg/kg of ketamine intramuscular 
and completing the Patient History Questionnaire (PHQ-9) before and 24-hours after receiving 
ketamine treatment, and the Psychedelic Experience Survey (PES) after their psychedelic 
experience. The PHQ-9 is a commonly used 9-item self-report depression survey given to 
patients to gather a snapshot of their depressive symptoms over a specific time period, (Arroll et 
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al., 2010); see Appendix B for details. The PES is a Likert-type survey given to patients after 
their ketamine treatment to gather the subjective quality of the psychedelic experience, 
specifically the intensity, positive content, negative content, dissociation, hallucination, and 
adverse side effects (nausea/vomiting). Patients are asked to rate the quality of the 
aforementioned characteristics of their psychedelic experience on 5-point Likert-type scale, by 
which higher rating indicates a stronger quality; see Appendix C for details.  
At Kadima Neuropsychiatry Institute, I reviewed patient charts to identify patients who 
had a primary diagnosis of treatment-resistant depression (inadequate response to their previous 
treatment trial) and received an initial intramuscular infusion of 0.25 mg/kg of ketamine. Of the 
146 patient charts reviewed, 34 patients were recognized as having treatment-resistant depression 
and had received an initial dose of 0.25 mg/kg of ketamine. The 34 patient charts were also 
reviewed to identify those who completed both pretreatment PHQ-9, PES, and 24-hour post 
treatment PHQ-9. A total of 8 patients at Kadima Neuropsychiatry Institute met these criteria and 
were added to the dataset containing 15 patients from Dr. Feifel’s UCSD outpatient clinic. It is 
important to note that the patient’s included in this project were self-referred or referred by their 
treating physicians and psychiatrists and were not recruited for the purpose of the study. Once 
the patients were identified, their demographics (i.e., date of birth and sex), pretreatment PHQ-9 
scores, PES scores, and 24-hour post treatment PHQ-9 scores were entered into the dataset using 
Microsoft Excel. The combined dataset was imported into a statistical package, R Commander, 
to run the appropriate analyses.  
A total of 23 patients were analyzed in this study. To determine the efficacy of ketamine 
treatment, I ran a Paired t-test between pretreatment PHQ-9 scores and 24-hour post treatment 
PHQ-9 scores. To determine which characteristic of a patient’s psychedelic experience or “trip” 
                              
 
ADVANCED THERAPY FOR TREATMENT-RESISTANT-DEPRESSION                           11 
 
was associated with the decrease in depressive symptoms, I ran a Pearson’s R correlation 
between the separate items on the PES (intensity, positive content, negative content, dissociation, 
hallucination, and nausea and vomiting) and the percent difference (post treatment score minus 
pretreatment score divided by the post treatment score) of a patient’s pretreatment PHQ-9 scores 
and 24 hour post treatment PHQ-9 scores. The dataset and initial analyses were provided to Dr. 
Feifel for further analysis and interpretation.  
The individuals involved in this project were the preceptor (Dr. David Feifel) and myself, 
the research associate. This project was set to take real world clinical data and provide it to the 
literature of the efficacy of ketamine, and determine the importance of characteristics within a 
psychedelic experience and a decrease in depressive symptoms. My personal goal during this 
project was to accurately identify patients who were appropriate for the analyses and provide 
sound research and data for my preceptor to further analyze and interpret.  
Health Impact 
Results 
The results of my fieldwork project at Kadima Neuropsychiatry Institute demonstrated 
the quick and efficacious effects of ketamine in decreasing depressive symptoms in real world 
patients with treatment-resistant depression. Additional analyses also demonstrated which 
characteristics of a patient’s ketamine-induced psychedelic experience are most likely associated 
with their decrease in depressive symptoms. The dataset analyzed in this retrospective study 
included patients from Dr. Feifel’s psychiatric outpatient clinic at UCSD (n=15) and Kadima 
Neuropsychiatry Institute (n=8).  
All analyses were ran through the statistical package R Commander. According to the 
samples pretreatment PHQ-9 scores, the patients as a whole were moderately depressed, (M = 
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17.83, SD = 5.47). To determine the efficacy of ketamine treatment, pretreatment PHQ-9 scores 
and 24-hour post treatment PHQ-9 scores were analyzed using a Paired T-test. There was a 
significant decrease in PHQ-9 scores after receiving an initial intramuscular dose of 0.25 mg/kg 
of ketamine, t (22) = 5.27, p < .001. The average PHQ-9 score dropped to 13. 43 (SD = 6.69) 24 
hours after receiving treatment, demonstrating quick antidepressant effects.  
Descriptive statistics of the samples PES score are in Appendix D. To determine which 
characteristic of ketamine-induced psychedelic experience was most associated with a patient’s 
depressive symptoms, Pearson correlations were ran between each item on the PES and the 
percent difference between pretreatment and 24-hour post treatment PHQ-9. There was a strong 
negative association between the intensity of a patient’s psychedelic experience and their percent 
difference in pretreatment and 24-hour post treatment PHQ-9 scores, r(21) = -0.69, p < .001. 
There was a strong negative association between a patient’s subjective positive experience and 
their percent difference in pretreatment and 24-hour post treatment PHQ-9 scores, r(21) = -0.59, 
p < .001. There was no association between a patient’s subjective negative psychedelic 
experience and their percent difference in pretreatment and 24-hour post treatment PHQ-9 
scores, r(21) = -0.14, p = .51. There was a significant negative moderate association between a 
patient’s dissociative experience during their psychedelic experience and their percent difference 
in pretreatment and 24-hour post treatment PHQ-9 scores, r(21) = -0.46, p < .02. There was no 
association between hallucinations during a patient’s psychedelic experience and their percent 
difference in pretreatment and 24-hour post treatment PHQ-9 scores, r(21) = -0.31, p = .15. 
Lastly, there was no association between adverse effects (nausea and vomiting) during a patient’s 
psychedelic experience and their percent difference in pretreatment and 24-hour treatment PHQ-
9 scores, r(21) = -0.24, p = .27. 
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The results of this retrospective study demonstrated the efficacious antidepressant effects 
of an initial intramuscular dose of 0.25 mg/kg of ketamine for the treatment of treatment-
resistant depression. Our results were consistent with the literature in that ketamine is a quick 
and efficacious option for individuals with treatment-resistant depression, (Drewniany et al., 
2015; Feifel et al., 2017; Kishimoto et al., 2016).  In addition, our exploratory analyses suggested 
that there is an important association of the intensity, positive content, and dissociative 
characteristics of a psychedelic experience and the decrease in depressive symptoms. To our 
knowledge, these exploratory findings are the first of its kind in regard to ketamine treatment for 
treatment-resistant depression. Although these consistent and new findings are key to addressing 
the need for more quick and efficacious treatments for depression, more research needs to be 
done to expand on and validate which characteristics of ketamine’s psychedelic “trip” are crucial 
to its antidepressant effects.  
Implications 
Given the inadequacy of standard treatment options for depression and the ever-growing 
prevalence of treatment-resistant depression, more research needs to delve into ketamine’s strong 
and quick antidepressant effects, as demonstrated in my fieldwork project, to unleash its true 
antidepressant potential. Although the results from this fieldwork project were informative, the 
sample was relatively small and only included San Diego based patients who can afford 
ketamine treatment, which was $400 for the initial dose of 0.25 mg/kg and a commitment to at 
least five subsequent treatments at the same price. Further ketamine research needs to increase 
sample selection and size to confirm the results account for all the variability in the general 
population, thus ensuring the results are generalizable. In addition, our exploratory analyses 
demonstrated broad characteristics of a psychedelic experience. The PES used in the study is 
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limited to broad categories without delving into specifics qualities of each characteristic. Future 
research needs to address this limitation and expand on what specific subjective experience is 
important to ketamine's antidepressant effects. Expanding on the specifics of the positive content 
of a psychedelic ketamine experience could be especially crucial to addresses opposing negative 
content associated with depression such as pessimistic thoughts and suicidal ideation and 
behavior.  
Given the exploratory results of my fieldwork project, future programs addressing severe 
depression and suicidality need to capitalize on the quick antidepressant and positive content 
emitting effects of ketamine treatment. To my knowledge, creating a mobile on demand 
ketamine clinic within our country would be the first of its kind. A start up pilot trial could be 
created to determine whether the ketamine treatment for severe depression associated with 
suicidality could overall decrease the risk of suicide within the United States. The prospective 
success of such a program could give positive insight into ketamine’s impact on mental health in 
the United States. Such success and impact could possibly lead to re-examining the policies 
restricting ketamine’s powerful potential.  
Despite being an available, yet expensive, treatment option for treatment-resistant 
depression, the therapeutic effects of ketamine seem to be restrained by current policy and 
regulations. Currently ketamine is listed as a schedule III drug controlled substance and is only 
the US Food and Drug Administration (FDA) approved as a general anesthetic; however, 
psychiatrist and anesthesiologist often use it “off-label” for treating chronic pain and treatment-
resistant depression. The Controlled Substances Act is a statute that establishes drug policies that 
regulate the professional and recreational use of drugs. Even though ketamine is not a strictly 
regulated schedule I or II substance, its street reputation and recreational history for abuse inhibit 
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researchers from important future research. Although the broad regulation on drugs are 
undeniably needed, ketamine and its newfound therapeutic effects for depression need our efforts 
to explore different policies that allow more research and utilization of its potential therapeutic 
uses. Expanding policy to increase the accessibility of ketamine would be a step closer to 
unleashing ketamine therapeutic potential for depression as well as exploring its potential for 
more indications. 
Conclusion 
This fieldwork project at Kadima Neuropsychiatry Institute focused on evaluating an 
advanced specialty treatment that addresses an ever-growing subcategory of major depressive 
disorder known as treatment-resistant depression. Although there are a number of standard 
psychological, pharmacological, and non-pharmacological treatment options for major 
depressive disorder, the majority of patients taking these standard treatments often report 
minimal to no improvement of their depressive symptoms. This reported inadequacy to standard 
treatment has been commonly defined as treatment-resistant depression, (Fava, 2003; Little, 
2009). To address this growing population, ketamine treatment has been demonstrated to be an 
efficacious antidepressant treatment for patients with treatment-resistant depression (Feifel et al., 
2016). Within my fieldwork project at Kadima Neuropsychiatry Institute with Dr. David Feifel, I 
evaluated the efficacy of an initial intramuscular dose of 0.25 mg/kg of ketamine administered 
intramuscular in real world patients with treatment-resistant depression, and explored which 
characteristic of their ketamine induced psychedelic experience or “trip” was most associated 
with the decrease in depressive symptoms. See Appendix E for Competency Matrix.  
After reviewing patient charts for individuals who consented to receiving ketamine 
treatment and partaking in the necessary self-report surveys, a total of 24 patients’ pretreatment 
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PHQ-9, PES, and 24-hour post treatment PHQ-9 scores were imported into a statistical package, 
R Commander, to analyze. The results of the analyses confirmed ketamine’s quick antidepressant 
effects and suggested that having an intense, positive, and dissociative psychedelic experience or 
“trip” are important characteristics in ketamine's antidepressant effects. Within the sample of this 
project, there was a significant decrease in a patient’s overall depressive symptoms within 24 
hours after receiving an initial dose of ketamine. Also, those that reported having an intense, 
positive, and dissociative experience during their ketamine induced psychedelic experience were 
more likely to indicate a decrease in their depressive symptoms.  
Although the demonstrated efficacy of ketamine in this project were consistent with the 
literature, more research needs to be done to strengthen the findings of this project by increasing 
the sample size and selection to give such results more inference and power. Furthermore, given 
the newfound importance of intensity, positive content, and dissociation within a ketamine 
induced psychedelic experience, a public health program, such as a mobile ketamine clinic, 
needs to be developed to capitalize on ketamine’s elicitation of an intense and positive 
experience in order to address the need of those who often ruminate on the negativity and 
suicidality. Given the findings of this project and the potential of ketamine as a therapeutic 
medication rather than just an analgesic, individuals suffering from treatment-resistant 
depression could experience such efficacious potential once current legislation and policies are 
expanded to allow ketamine to be further researched for its quick and therapeutic properties.  
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